Denali Therapeutics (NASDAQ:DNLI) Upgraded at William Blair

William Blair upgraded shares of Denali Therapeutics (NASDAQ:DNLI - Free Report) to a strong-buy rating in a report released on Thursday morning,Zacks.com reports.

Several other research firms have also issued reports on DNLI. B. Riley reiterated a "buy" rating and set a $35.00 target price (down from $38.00) on shares of Denali Therapeutics in a report on Wednesday, March 5th. Morgan Stanley began coverage on shares of Denali Therapeutics in a research note on Friday, March 7th. They set an "overweight" rating and a $33.00 target price for the company. Cantor Fitzgerald raised shares of Denali Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Thursday, April 10th. JPMorgan Chase & Co. cut their price objective on shares of Denali Therapeutics from $28.00 to $24.00 and set an "overweight" rating for the company in a research report on Tuesday, January 7th. Finally, Robert W. Baird assumed coverage on shares of Denali Therapeutics in a report on Tuesday, January 7th. They issued an "outperform" rating and a $31.00 target price for the company. One equities research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, Denali Therapeutics has an average rating of "Buy" and an average target price of $37.57.

Denali Therapeutics Stock Performance

Shares of NASDAQ DNLI traded up $0.25 during mid-day trading on Thursday, hitting $16.50. The stock had a trading volume of 1,521,238 shares, compared to its average volume of 1,082,452. Denali Therapeutics has a 1 year low of $10.57 and a 1 year high of $33.33. The business has a 50 day moving average price of $14.74 and a two-hundred day moving average price of $20.68. The firm has a market cap of $2.40 billion, a P/E ratio of -5.98 and a beta of 1.58.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.75) by $0.08. Equities research analysts predict that Denali Therapeutics will post -2.71 EPS for the current fiscal year.

Hedge Funds Weigh In On Denali Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of DNLI. Sterling Capital Management LLC boosted its holdings in shares of Denali Therapeutics by 589.9% in the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock worth $36,000 after purchasing an additional 1,516 shares during the period. GF Fund Management CO. LTD. purchased a new position in shares of Denali Therapeutics in the 4th quarter worth approximately $62,000. Point72 Hong Kong Ltd purchased a new position in shares of Denali Therapeutics in the 4th quarter worth approximately $65,000. PNC Financial Services Group Inc. boosted its holdings in shares of Denali Therapeutics by 30.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock worth $77,000 after purchasing an additional 885 shares during the period. Finally, GAMMA Investing LLC boosted its holdings in shares of Denali Therapeutics by 253.8% in the 1st quarter. GAMMA Investing LLC now owns 7,953 shares of the company's stock worth $108,000 after purchasing an additional 5,705 shares during the period. Hedge funds and other institutional investors own 92.92% of the company's stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.